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Abstract
Background: Considerable racial and socio-economic disparities exist in breast cancer. In spite of the existence of
numerous evidence-based interventions (EBIs) aimed at reducing breast cancer screening barriers among the
underserved, there is a lack of uptake or sub-optimal uptake of EBIs in community and clinical settings. This study
evaluates a theoretically based, systematically designed implementation strategy to support adoption and
implementation of a patient navigation-based intervention, called Peace of Mind Program (PMP), aimed at
improving breast cancer screening among underserved women.
Methods/design: The PMP will be offered to federally qualified health centers and charity clinics in the Greater
Houston area using a non-randomized stepped wedge design. Due to practical constraints of implementing and
adopting in the real-world, randomization of start times and blinding will not be used. Any potential confounding
or bias will be controlled in the analysis. Outcomes such as appointment adherence, patient referral to diagnostics,
time to diagnostic referral, patient referral to treatment, time to treatment referral, and budget impact of the
intervention will be assessed. Assessment of constructs from the consolidated framework for implementation
research (CFIR) will be assessed during implementation and at the end of the study (sustainment) from each
participating clinic. Data will be analyzed using descriptive statistics (chi-square tests) and generalized estimating
equations (GEE).
Discussion: While parallel group randomized controlled trials (RCT) are considered the gold standard for evaluating
EBI efficacy, withholding an effective EBI in practice can be both unethical and/or impractical. The stepped wedge
design addresses this issue by enabling all clinics to eventually receive the EBI during the study and allowing each
clinic to serve as its own control, while maintaining strong internal validity. We expect that the PMP will prove to
be a feasible and successful strategy for reducing appointment no-shows in underserved women.
Trial registration: Clinical trials registration number: NCT02296177
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Background
Importance of mammography adherence in underserved
women
Breast cancer is the most common cancer and the second
leading cause of cancer mortality among women in the
USA [1], with roughly one in eight women developing
breast cancer during their lifetime [2, 3]. Substantial breast
cancer-related morbidity and mortality disparities persist
among the underserved, particularly among African
American women [1–6]. Disparities in breast cancer out-
comes are due to lower mammography screening rates,
lack of timely follow-up of abnormal results, and lack of
timely treatment initiation among women with breast
cancer. Stage at diagnosis is an important predictor of sur-
vival [7, 8]. Women who are diagnosed at a late stage are
at higher risk for mortality from breast cancer, and are at
risk for complications and overall poorer health outcomes
[7, 8]. Underserved populations have consistently been
shown to be at higher risk for late-stage diagnosis due to a
combination of lower screening rates, missed appoint-
ments, and lack of timely referral to diagnostic evaluation
and treatment [7–11]. Additionally, research has found
that past mammography screening behavior is strongly
correlated with current screening behavior, meaning that
women who are off-schedule with screening are less likely
to become adherent [12]. Appointment no-shows as they
relate to the eventual completion of mammography
screening have also been recently studied. Ontilo et al.,
2013, found that women who missed a screening were
more likely to be diagnosed at a later stage of cancer than
women who attended [1]. In a 2012 study by Fayanju et al.
of federally qualified health center (FQHC) patients in St.
Louis, women who missed a screening appointment were
significantly more likely to never receive definitive diagnosis
or needed follow-up care [13]. A number of barriers
prevent underserved women from obtaining timely screen-
ing, including patient-level socioeconomic differences like
education, insurance, and income; differences in skills and
qualifications of providers attending to different racial-
ethnic groups; inadequacies in health care systems which
provide care for the underserved; beliefs and misconcep-
tions; and linguistic/communication barriers [8, 9, 14, 15].
A number of evidence-based intervention programs have
been developed to address these barriers, yet disparities in
breast cancer outcomes persist for underserved women.
One reason for this may be the lack of uptake and use of
evidence-based interventions in community and clinical
settings that serve these women [16–20].
The need for adoption and implementation support in
clinics serving underserved populations
Dissemination and implementation processes for the up-
take of evidence-based interventions (EBIs) remain poorly
understood. The expertise of practitioners is often not used
effectively, and implemented programs often do not ultim-
ately reflect the needs of underserved communities within
the specific context [17, 21, 22]. Particularly for interven-
tions with minority communities, EBIs should be adopted
and tailored at the community level by partnerships that
include both researchers and practitioners, adding an add-
itional level of complexity to the translation of these EBIs
[23, 24]. Efforts to increase adoption and use of EBIs in
community and clinical settings serving underserved
women should target the safety net health care delivery
system [25]. Within the safety net, primarily FQHCs and
charity clinics provide comprehensive primary health care
services for underserved communities regardless of ability
to pay; this includes mammography screening [25, 26].
Additionally, the passage of the Affordable Care Act has
significantly expanded the role of FQHCs who will be
increasingly important in providing care for populations
with a disproportionate burden of need [25]. Due to their
client base, FQHCs are uniquely situated to reach and serve
women in the most need for breast cancer screening [25];
however, FQHCs need assistance in planning and imple-
menting EBIs [27, 28]. There is currently a lack of theor-
etically informed, well-documented, and evaluated
implementation strategies for the translation of EBIs
particularly within safety net clinical settings [4, 5].
Systematically designed implementation strategies are
particularly important for the implementation of complex
interventions—meaning interventions consisting of mul-
tiple behavioral, technological, and organizational compo-
nents [3].
Trial objectives
This study aims to address the research to practice gap and
uses a theoretically based, strongly designed D&I strategy
to support implementation of a breast cancer screening
intervention aimed at promoting mammography adherence
in underserved populations. Our patient navigation-based
breast cancer screening intervention for the underserved is
called the Peace of Mind Program (PMP). PMP is an EBI
which was adapted from a National Cancer Institute
Research tested intervention program and uses a tailored
telephone counseling reminder call based on the Trans-
theoretical Model of Change to counsel patients through
barriers to appointment attendance [20, 29–31]. PMP
builds on our previous intervention protocol [30, 31] by
adding intervention components to specifically support
implementation within safety net clinics.
We hypothesize that the PMP intervention will im-
prove mammography appointment adherence as com-
pared to usual practice.
The specific objectives are:
1. To assess implementation of the intervention at the
clinics.
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2. To test the effectiveness of the PMP intervention in
improving appointment adherence for screening
mammograms.
3. To test the effectiveness of the PMP intervention in
reducing the time it takes for a patient with
abnormal results to receive follow-up and navigation
to a diagnostic appointment and subsequent treat-
ment initiation.
4. To assess the budget impact (cost savings) of the
implementation of the PMP intervention from the
perspective of the clinics.
Methods
Trial design
We will conduct a non-randomized stepped wedge design
as shown in Fig. 1. Each clinic will serve as its own control
and will not have access to the PMP prior to implementa-
tion. Clinics will implement the PMP for up to 47 weeks
depending on their group assignment (see Fig. 1). The trial
will follow the CONSORT extension for stepped wedge
randomized trials reporting guidelines (see Additional file
1). Insert reference: [Hemming K, Girling A, Haines T, et
al. Protocol: Consort extension to stepped wedge cluster
randomised controlled trial. 2014].
Participants and settings
The PMP trial will be conducted in FQHCs and charity
clinics who are members of the Breast Health Collaborative
of Texas (BHCT) network. BHCT is a state-wide network of
over 700 clinics and individuals with a shared mission to im-
prove access to breast health services for all women in Texas.
Practice inclusion criteria
In order to participate, clinics must (1) be members of
BHCT within the Houston service area, (2) have a designa-
tion as a FQHC by HRSA or be a charity clinic which pro-
vides free or reduced cost care to underserved populations
in their service area, (3) be serving women between the ages
of 40–64 who are at or below 200 % of the federal poverty
level for a family of four and who lack health insurance, and
(4) engage in provision of mammography screening services
at least six times per year and (5) women at the clinic must
be in need of mammography screening and be scheduled for
an upcoming appointment. Patients must have completed a
clinical breast exam prior to their screening appointment.
Practice exclusion criteria
There are no practice exclusion criteria if serving pa-
tients within the Houston service area.
Intervention components
The PMP intervention program consists of the following
components: a financial incentive of $7500 to the clinic for
participation; funding for screening mammograms for
women with documented financial need; coordination of
increased screening within each clinic (the research team
has established partnerships with local mobile mammog-
raphy providers to assist in increasing screening capacity);
8 h of state certified training for staff in the EBI’s reminder
Fig. 1 Stepped wedge trial design
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phone call protocol [20, 30, 31]; stakeholder review of pro-
gram adaptation and implementation materials; stakeholder
meetings to troubleshoot implementation issues as they
arise and to develop and disseminate e-newsletters and re-
ports which highlight success stories and re-inforce desired
behaviors; technical support for implementation (imple-
mentation manuals, clinic manuals, stakeholder manuals);
and assistance in data tracking and reporting and budget
impact analysis.
Sample size
Sample size for the stepped wedge design is calculated
using the formula of Woertman et al. 2013 [32], which
corrects a standard sample size calculation for two inde-
pendent proportions as follows:
Nsw ¼ Nu  DEsw
where Nu equals the uncorrected sample size estimate
and DEsw is the design effect for the stepped wedge
design.
DEsw ¼ 1þ ρ ktnþ bn−1ð Þ
 3 1−pð Þ




where ρ equals the intraclass correlation, k equals the
number of steps, b equals the number of baseline mea-
surements, t equals the number of intervention mea-
surements, and n equals cluster size. The uncorrected
sample size for a difference in two independent propor-
tions assuming a baseline no-show rate of 35 % reduced
to 28 %, an α of 0.05 and a power of 0.9 equals 924 per
group. The average no-show rate and expected reduction
in no-shows are based on pilot studies [20, 30]. The
intraclass correlation coefficient (ICC), p, for mammog-
raphy screening interventions has been shown to range
from 0.0009 to 0.22 in community-based trials with an
average ICC of 0.06 based on recent systematic reviews
[33, 34]. Estimated sample sizes based on these parame-
ters are summarized in Table 1. Based on the average
reported ICC, the required sample size is 388 women.
The required number of clusters is calculated as Nsw/n
resulting in an effective sample size requirement of seven
clusters (clinics) [32]. In order to account for potential
attrition estimated based on the investigator’s pilot study,
the sample size will be increased by 20 % to 466 women
across nine clinics.
Randomization and allocation
Clinic will be the unit of allocation in this study. Each
clinic will be assigned a start date in groups of three
(Fig. 1). Randomization of clinic start dates will not be
done for practical reasons, including constraints in clinic
operations (requirements for when they can or cannot
start) and available screening dates (some clinics need
additional time to reach the screening minimums required
for study participation (n = 6)). The research team will as-
sign a start date to each clinic based on these constraints.
Blinding
Due to the nature of the intervention, it is not possible
to blind the clinics or the research team in this study.
However, outcome assessment is objective as we are
using medical records to obtain screening outcomes. It
is also not possible to blind the data analyst because the
analysis is designed as a time series in which every clinic
receives the intervention rather than a comparison be-
tween groups. The analysis will be pre-specified rather
than blinded, and any analysis not pre-specified will be
clearly delineated and considered hypothesis generating/
exploratory rather than hypothesis testing/explanatory.
Outcome measures
The primary outcome measure will be appointment ad-
herence comparing the intervention period to the base-
line period in each clinic. Appointment adherence will
be considered using the following categories: no-show,
not attended-called, late-screened, late-turned away, can-
celed/re-scheduled, and ineligible. A no-show will be
considered a patient who makes no contact with the clinic
prior to the appointment and does not attend on the day
of mammography screening. A not attended-called is a
patient who calls the clinic the day of the screening and
asks to cancel or re-schedule (this may occur before or
after their designated appointment time). Late-screened is
a patient who arrives more than 30-min late for their
appointment but is still seen by the mammography pro-
vided (e.g., worked in). Late-turned away is a patient who
is more than 30-min late for their appointment and is
turned away by the provider. A cancel or re-schedule is a
patient who calls more than 24 h in advance to cancel or
change their appointment date. An ineligible patient is a
woman with symptoms who is ineligible to receive a
screening mammogram and is turned away for a diagnostic
evaluation or a woman who is turned away for incomplete
paperwork. These categories are based on an assessment of
the mammography providers’ and clinics’ behavior and the
ways in which patient appointment outcomes are consid-
ered within a clinic system. Secondary measures will in-
clude patient referral to diagnostic (following screening) as
Table 1 Estimated sample sizes based on ICC reported values
Nsw Nu DEsw p (ICC)
370 1848 0.20 0.006
388 1848 0.21 0.06
370 1848 0.20 0.1
333 1848 0.18 0.22
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a binary outcome and amount of time the referral took in
days, patient referral to treatment as a binary outcome and
the amount of time it took in days, and measures of imple-
mentation in each clinic based on the consolidated frame-
work for implementation research (CFIR). A survey made
up of scales assessing various CFIR constructs was devel-
oped by the Cancer Prevention and Control Research
Network (CPCRN); we will use several scales from that sur-
vey in this study. These constructs will be measured at
baseline (adoption), 8-week post-implementation, and fol-
lowing the end of the trial period (sustainment) [35–37].
Because randomization of start dates is not possible, we will
control for potential confounders in the analysis of the data.
Control variables may include time to intervention start
date in each clinic, clinic size, staffing, and whether or not
the clinic had a pre-existing patient navigation program
for breast cancer screening, patient demographics, region
served, and infrastructure characteristics (e.g., funding)
(taken from the Health Resources and Services Adminis-
tration Uniform Data System (UDS) reports for FQHCs
and our economic survey).
Data collection
Data collection protocols will be standardized across all
clinics. In clinics with the capability to collect and report
data from their electronic health record (EHR), the re-
search team will seek to adapt the existing system for
data collection. In clinics where the EHR is not easily
modified or one is not available, data collection will be
supported via the use of a customized Redcap database.
The database will have a front-facing data entry interface
which is user friendly and supports accurate data collection
for statistical analysis. The patient navigator (or imple-
menter) in each clinic will be responsible for tracking up-
coming patient mammography appointments, reminder
phone call attempts, patient consent for the trial, and the
EBI screening questions and barriers counseled during the
phone call. Appointment attendance, referral to diagnostic
mammography, and treatment data will be abstracted from
medical records in each clinic. For the budget impact ana-
lysis, two surveys will be used to assess the FQHC/clinic
resource utilization before and after the implementation of
the intervention. We are also collecting patient resource
utilization data to understand what parts of patient
costs are being subsidized by the FQHCs/clinics and to
also ensure availability of cost information from patient
perspective in case an economic evaluation from soci-
etal perspective is deemed important.
Statistical methods
Descriptive statistics will be calculated for all primary
and secondary measures. Following descriptive analysis,
regression modeling will be used to evaluate outcomes
while allowing for control of potential confounders
(e.g., time, clinic size, staffing, and whether or not the
clinic had a pre-existing patient navigation program
for breast cancer screening). Due to the correlated na-
ture of the data and repeated observations taken on
each clinic, generalized estimating equations (GEE)
will be used to model outcomes while allowing us to
control for potential confounders [38, 39]. GEE is used
to estimate the parameters from a generalized linear
model when there is possible correlation between out-
comes [38, 39]. GEE is a population averaged model
that estimates the average response from a change in a
covariate over the population rather than individual
[38, 39]. GEE model estimates are less sensitive than
generalized linear mixed models to the specification of
the variance structure in the data making them a flex-
ible choice [38, 39]. Data on appointment adherence
will be analyzed using various sub-groups to evaluate
the intervention effect. For example, no-shows and
not attended-called may be combined to consider a
more stringent definition of a no-show. They will also
be analyzed separately. We expect the intervention to
have an effect on the no-shows, not attended-called, late-
screened, late-turned away and ineligible categories and will
evaluate that effect separately. Sub-categories will be com-
pared using chi-square tests to determine differences in
outcomes between groups (control and intervention). Data
from the CFIR survey will be analyzed using descriptive
statistics and in the regression models to evaluate which
constructs are related to implementation outcomes. Data
analysis will be conducted in Stata (Stata Corp., College
Station, TX).
Budget impact analysis
The annual budget impact analysis (BIA) will be per-
formed from the perspective of the clinics [40, 41]. The
aim of the BIA is to assess the additional cost each clinic
will incur to implement and sustain the EBI. The popu-
lation of interest for the BIA will be the patients served
by each clinic who are eligible to receive a mammogram
for each year under study. Each patient will be the unit
of analysis for the purpose of estimating the volume and
resources required. The dollar value and the price rates
for the expenditures incurred by each clinic will be stan-
dardized at the final year of the study for the BIA. This
standardization will circumvent the need to use discount
factors and inflation adjustment for the annual BIA values
pertaining to each year of the study. The average cost per
year will be computed for three different time periods:
(1)The pre-intervention/control period, which will give
us a distribution of cost for the screening reminder
or navigation systems currently used by the clinics.
We expect to find a wide variety of patient naviga-
tion or screening reminder systems during this
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period. Many clinics might have no mechanism in
place for navigation or screening reminders for
mammogram eligible patients.
(2)The intervention period, which will help estimate the
initial investment and implementation cost associated
with the EBI. Cost associated with this period will be
the highest among the three periods and will provide
an estimate of the upfront expenses for any new clinic
establishing an EBI program. It will consists of the
fixed cost of training the navigators on the EBI
methods, cost associated with structural changes to
the clinic’s EMR, which will help link the patient
records with the appropriate EBI scripts, and cost of
developing web-based scripts for patient navigation.
Based on the volume of patients served, the interven-
tion period cost will also include the variable cost of
hiring additional navigators for implementing the EBI.
The navigators will not only help improve the
provision of mammograms but also facilitate diagnos-
tic test administration and treatment initiation for
patients who need these. The patient volume and
amount of time required per patient will be obtained
during the implementation period from each of the
clinics. The initial time required to navigate a patient
and improve adherence to the mammogram screen
will be similar between patients. However, if the pa-
tient has a positive mammogram, the patient will re-
quire further navigation to obtain a diagnostic test
(biopsy). Patients with positive diagnostic tests will
also require navigation for treatment initiation. Al-
though the study’s primary goal is to improve screen-
ing adherence and reduce screening “no-show” rates,
the navigators are also involved with diagnostic and
treatment navigation when required by the patient.
Hence, cost of those tasks will also be included in the
analysis.
(3)The post-intervention period, which will help estimate
the steady state cost for each clinic with no external
support for the EBI. Post-intervention provision of
EBI and associated costs will be obtained 3 months
after the end of the study.
Trial status
The trial has completed enrollment of the first wave of
clinics (n = 9) and is currently collecting baseline measures
at these locations. Baseline measures include appointment
adherence outcomes as described above, the clinic and
patient resource utilization survey for the budget impact
analysis, and CFIR survey. All participating clinics have
completed the baseline CFIR survey. Based on the number
of mammography screening drives at each clinic, we
anticipate enrolling approximately 2200 women into the
first wave of the trial.
Discussion
Rationale for the stepped wedge design
While parallel group randomized controlled trials
(RCT) are considered the gold standard for evaluat-
ing EBI efficacy, withholding an effective EBI in
practice can be seen as unethical and/or impractical
[42–45] . The stepped wedge design addresses this
issue by enabling all clinics to eventually receive the
EBI during the study and allowing each clinic to
serve as its own control, while maintaining strong
internal validity [42–45]. Stepped wedge designs are
particularly useful when the intervention is thought
to do more good than harm and when an RCT is
impractical, as is the case in this study (e.g., finan-
cial, logistical reasons) [45–47].
Anticipated challenges
Despite the advantages to using a stepped wedge design for
the PMP trial, we anticipate a number of challenges. The
staggered entry into the intervention period means that
clinics assigned to a later start date will start the interven-
tion 48 weeks after their initial agreement to adopt the pro-
gram. This may mean that the motivations for initially
agreeing to adopt the program may no longer apply. We
also anticipate that clinics may be frustrated by having to
wait to start the program even if they stay motivated to par-
ticipate. With that in mind, we defined a strategy to main-
tain clinic interest and engagement while they are waiting
to start PMP. Each clinic will participate in a stake-
holder committee where they will review implementa-
tion plans, handbooks, and undergo intervention
training. The schedule for the stakeholder committee
is staggered such that the later groups spend more
time working in this venue in order to keep them en-
gaged. A further potential problem in stepped wedge
designs is contamination between clinics and those
waiting for the intervention. It is possible that some
clinics may change their procedures based on what
they hear or see with other participating clinics. How-
ever, we expect such effects to be mild because mean-
ingful and sustained improvements in mammography
appointment adherence require systematic and pro-
longed effort that is unlikely to occur before the PMP
training is completed.
Ethical approval
This study has received approval from the Institu-
tional Review Board at the University of Texas Health
Science Center Houston. The protocol number is
HSC-SPH-14-0269. Verbal consent will be obtained
for patients participating in the EBI reminder phone
calls. Written consent will be obtained for economic
data collection from patients.
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